3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Hepatocellular
9
Carcinoma, Non-Small-Cell Lung
8
Esophageal Squamous Cell Carcinoma
7
Stomach Neoplasms
4
Recurrence
4
Neoplasm Metastasis
4
Head and Neck Neoplasms
4
Lung Neoplasms
3
Colorectal Neoplasms
3
Advanced Solid Tumors
3
Advanced Solid Tumor
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Esophageal Neoplasms
2
Uterine Cervical Neoplasms
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
NSCLC
1
Multiple Pulmonary Nodules
1
Mid-low Rectal Cancer
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Cisplatin
15
Gemcitabine
7
Fluorouracil
6
Docetaxel
6
Radiotherapy, Intensity-Modulated
5
Oxaliplatin
4
Capecitabine
4
pembrolizumab
3
Radiotherapy
3
Carboplatin
3
Acupuncture Therapy
3
Psychiatric Rehabilitation
2
Paclitaxel
2
Nicotine
2
Counseling
2
Cetuximab
2
Celecoxib
2
Bupropion
2
tislelizumab
1
spartalizumab
1
sargramostim
1
motexafin gadolinium
1
fosaprepitant
1
fialuridine
1
endostar protein
1
cc-486
1
apatinib
1
Zoledronic Acid
1
Zinc Oxide
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Nasopharyngeal Neoplasms
×
tislelizumab
×
Clear all
NCT03924986
2025-01-31
RATIONALE-309
BeiGene
Phase 3
Completed
263 enrolled
19 charts